Literature DB >> 24756855

Prognostic value of cytoplasmic expression of S100A4 protein in endometrial carcinoma.

Hye In Chong1, Jeong Hee Lee2, Man Soo Yoon1, Dong Soo Suh1, Kyungbin Kim2, Jee Yeon Kim2, Kyung Un Choi2.   

Abstract

The S100A4 protein, a member of the S100 family of calcium-binding proteins, has been considered as a candidate prognostic marker in patients with cancer. The present study was conducted to evaluate the prognostic value of S100A4 and to examine its correlation with the clinicopathological parameters and the overall survival and progression-free survival in patients with endometrial carcinoma (EC). To do this, we performed immunohistochemistry of formalin-fixed tissue sections obtained from 135 cases of EC. In addition, we quantified the level of S100A4 mRNA using the quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). The cytoplasmic expression of S100A4 protein was observed in 35 cases (25.9%). There was a significant association between the expression of S100A4 and clinicopathological parameters such as histologic grade, FIGO stage, lymph node metastasis and loss of progesterone receptor (PR). qRT-PCR demonstrated that the level of S100A4 mRNA was significantly higher in ECs as compared with normal endometrium. The cytoplasmic expression of S100A4 had a significant correlation with shorter overall survival and progression-free survival on the Kaplan-Meyer survival analysis. In multivariate analysis, there was a significant correlation between S100A4 expression and a poorer OS. In conclusion, our results indicate that S100A4 may be a biological marker indicating the recurrence and poor prognosis in patients with EC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756855     DOI: 10.3892/or.2014.3149

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.

Authors:  Bader Alanazi; Chinmay R Munje; Namrata Rastogi; Andrew J K Williamson; Samuel Taylor; Paul S Hole; Marie Hodges; Michelle Doyle; Sarah Baker; Amanda F Gilkes; Steven Knapper; Andrew Pierce; Anthony D Whetton; Richard L Darley; Alex Tonks
Journal:  Leukemia       Date:  2019-10-14       Impact factor: 11.528

2.  Knockdown of ferritin heavy chain (FTH) inhibits the migration of prostate cancer through reducing S100A4, S100A2, and S100P expression.

Authors:  Cuixiu Lu; Huijun Zhao; Chenshuo Luo; Ting Lei; Man Zhang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.